PRESS RELEASE published on 10/21/2025 at 10:42, 1 month 14 days ago Franchissement de seuils Déclaration de franchissement de seuils par Vester Finance pour ADOCIA avec 889 555 actions, 4,86% du capital et 4,36% des droits de vote Déclaration Actions Franchissement De Seuils ADOCIA Vester Finance
BRIEF published on 10/15/2025 at 08:50, 1 month 20 days ago Résultats positifs pour l'insuline BioChaperone® Lispro en Phase 3 Essai Clinique Diabète De Type 1 ADOCIA BioChaperone® Tonghua Dongbao
BRIEF published on 10/15/2025 at 08:50, 1 month 20 days ago Positive results for BioChaperone® Lispro insulin in Phase 3 Clinical Trial Type 1 Diabetes ADOCIA BioChaperone® Tonghua Dongbao
PRESS RELEASE published on 10/15/2025 at 08:45, 1 month 20 days ago Inside Information / Other news releases ADOCIA and Tonghua Dongbao announce positive Phase 3 results for Ultra-Rapid Insulin BioChaperone Lispro in Type 1 Diabetes treatment, showing non-inferior HbA1c reduction and improved blood glucose control post-meal Type 1 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
PRESS RELEASE published on 10/15/2025 at 08:45, 1 month 20 days ago Informations privilégiées / Autres communiqués Adocia et Tonghua Dongbao annoncent des résultats positifs d'essai clinique de Phase 3 sur l'insuline BioChaperone® Lispro THDB0206 injection pour le Diabète de Type 1 en Chine Diabète De Type 1 ADOCIA Tonghua Dongbao Insuline BioChaperone Lispro
BRIEF published on 07/25/2025 at 08:50, 4 months 10 days ago Adocia and Tonghua Dongbao Report Phase 3 Success for Ultra-Rapid Insulin Diabetes Treatment Clinical Trial Phase 3 Results ADOCIA BioChaperone® Lispro
BRIEF published on 07/25/2025 at 08:50, 4 months 10 days ago Adocia et Tonghua Dongbao annoncent le succès de la phase 3 de leur projet d'insuline ultra-rapide Essai Clinique Traitement Du Diabète ADOCIA Résultats De La Phase 3 BioChaperone® Lispro
PRESS RELEASE published on 07/25/2025 at 08:45, 4 months 10 days ago Inside Information / Other news releases Adocia and Tonghua Dongbao announce positive Phase 3 results of Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in Type 2 Diabetes. Significant HbA1c reduction and improved post-meal blood glucose levels compared to Humalog® Type 2 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
PRESS RELEASE published on 07/25/2025 at 08:45, 4 months 10 days ago Informations privilégiées / Autres communiqués ADOCIA et Tonghua Dongbao annoncent des résultats positifs de l'essai clinique de Phase 3 sur l'insuline ultra-rapide BioChaperone® Lispro pour le diabète de Type 2 en Chine Essai Clinique Diabète De Type 2 ADOCIA Tonghua Dongbao Insuline Ultra-rapide
BRIEF published on 04/04/2025 at 11:21, 8 months ago Vester Finance réduit sa participation dans ADOCIA Droits De Vote Franchissement De Seuil Actions ADOCIA Vester Finance
Published on 12/05/2025 at 02:35, 5 hours ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 35 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 30 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 35 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 35 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 5 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 44 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 10 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 20 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 20 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 35 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 35 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 50 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 50 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
